Abstract

BackgroundGlobal functioning of patients with spondyloarthritis (SpA) can be influenced by many different factors. ASAS Health Index (ASAS HI) has aims to measure global functioning in patients with SpA. So...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Global Functioning in Axial Spondyloarthritis is Stronger Associated With Disease Activity and Function Than With Mobility and Radiographic Damage.
Ilka Schwarze ... Maria Kabelitz
Arthritis care & research | VOL. -
Ilka Schwarze, et. al.Ilka Schwarze ... Maria Kabelitz
04 Oct 2023
FRI0286 Burden of the disease in axial spondyloarthritis
S.A Rao ... J Sieper
Annals of the Rheumatic Diseases | VOL. 71
S.A Rao, et. al.S.A Rao ... J Sieper
01 Jun 2013
Development and validation of the Edmonton Ankylosing Spondylitis Metrology Index
Lisa Zappala ... Anthony S Russell
Arthritis Care & Research | VOL. 55
Lisa Zappala, et. al.Lisa Zappala ... Anthony S Russell
27 Jul 2006
Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Karel Pavelka ... Hana Hulejova
Arthritis research & therapy | VOL. 18
Karel Pavelka, et. al.Karel Pavelka ... Hana Hulejova
25 Nov 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers